IQV
IQV
US46266C1053
IQVIA Holdings, Inc.
Loading chart...

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Latest News

Related stocks

WAT
WAT • United States
Waters Corporation
433.77 USD
42.59B USD 1Y +31%
A
A • United States
Agilent Technologies, Inc.
170.54 USD
48.08B USD 1Y +19.4%
ILMN
ILMN • United States
Illumina, Inc.
278.17 USD
42B USD 1Y +170.6%
IDXX
IDXX • United States
IDEXX Laboratories, Inc.
518 USD
40.86B USD 1Y -18.5%
NTRA
NTRA • United States
Natera, Inc.
400.71 USD
57.76B USD 1Y +127.1%
MEDP
MEDP • United States
Medpace Holdings, Inc.
612.05 USD
17.08B USD 1Y +13.5%
LH
LH • United States
Labcorp Holdings Inc.
312.15 USD
25.32B USD 1Y +13.2%
RVTY
RVTY • United States
Revvity, Inc.
154.18 USD
17.2B USD 1Y +65.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
34.7% p.a.
Max Drawdown (5Y)
-51.5%
Sharpe Ratio (5Y)
-0.03
Beta Factor
1.17
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 258%.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (34.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -51.5% in the extended horizon.
ende